Greg Cima

Articles Authored by Greg Cima
Siemens Healthineers Q1 Dx Revenues Fall 21 Percent; Firm Strikes Lab Analyzer Deal With Unilabs
A decline in demand for rapid COVID-19 antigen tests dragged on the company's diagnostics division while lockdowns in China reduced routine testing.
Hologic Fiscal Q1 Revenues Fall 27 Percent as COVID-19 Assay Sales Continue Slide
The firm beat predictions for the quarter on the strength of its other molecular diagnostics business, and it predicts double-digit revenue growth for the year.
The firm is developing a shoebox-size gas chromatography instrument that could be used for routine screenings and critical illness detection and monitoring.
The Cue Health-sponsored ImmunoCare study is testing the value of giving immunocompromised people at-home tests, telemedicine, and prescription delivery.
Hologic Aims to Expand Global Reach With Focus on Women's Health
At the JP Morgan Healthcare conference, CEO Steve MacMillan especially noted Africa as an underserved market for women's health.
Aided by COVID-19 Funding, Firms Continued Developing Handheld Diagnostic Instruments in 2022
Premium
The lightweight, portable instruments coming onto the market employ promise to deliver test results closer to patients, potentially hastening treatments.
State labs and commercial companies see rising spinal muscular atrophy test volumes as screening programs launch in US states and European countries, among others.

Through $1.15B NIH Project, Researchers Look for Markers of Long COVID for Potential Dx Tests
Premium
The four-year National Institutes of Health-funded project is coordinating hundreds of researchers with goals of determining the causes and effects of long COVID.

With its Handheld Lab, Nostics Aims for Faster, Cheaper Point-of-Care Bacterial Pathogen Testing
Premium
The Netherlands-based firm said its Raman spectroscopy instrument can detect and differentiate bacteria in minutes and help reduce unnecessary antimicrobial use.
The firm said it will cut costs and streamline operations by consolidating its immunoassay and clinical chemistry offerings into the Atellica Solution lineup and phase out older platforms.